Tech Transfer Roundup: Mustang, Juno Advance Efforts With Immuno-Oncology
While Mustang was acquiring CAR-T intellectual property from Harvard and Juno licensed gamma-secretase inhibitor IP from OncoTracker and Fred Hutchinson for use with its CAR-Ts, Ocugen and Tamid licensed gene therapy research for ophthalmic uses.
You may also be interested in...
J.P. Morgan Notebook Day 3: Lilly's CGRP Prospects, Juno On Track, Color From Alnylam's Greene, Shire's New CMO
Daily round-up of news and notes from the 2018 J.P. Morgan Healthcare Conference in San Francisco: Lilly CEO on CGRP reimbursement jitters, Alnylam president on Sanofi deal terms, Juno stakes BCMA myeloma claim, Shire's new CMO.
Celgene's partnership strategy paid off at ASH with positive results for two CAR-T therapies in development with bluebird bio and Juno. The company is pursuing first- and best-in-class opportunities with the goal of becoming a leader in the CAR-T field.
Emerging Company Profile: The two-year-old company combines the Fortress Biotech model with City of Hope's broad expertise in CAR-T technology, plus leadership from a pioneer in the space.